FR2767323B1 - LINEAR PEPTIDES DERIVED FROM ANTIBIOTIC PEPTIDES, THEIR PREPARATION AND THEIR USE FOR VECTORIZING ACTIVE SUBSTANCES - Google Patents

LINEAR PEPTIDES DERIVED FROM ANTIBIOTIC PEPTIDES, THEIR PREPARATION AND THEIR USE FOR VECTORIZING ACTIVE SUBSTANCES

Info

Publication number
FR2767323B1
FR2767323B1 FR9710297A FR9710297A FR2767323B1 FR 2767323 B1 FR2767323 B1 FR 2767323B1 FR 9710297 A FR9710297 A FR 9710297A FR 9710297 A FR9710297 A FR 9710297A FR 2767323 B1 FR2767323 B1 FR 2767323B1
Authority
FR
France
Prior art keywords
preparation
active substances
peptides
antibiotic
linear
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9710297A
Other languages
French (fr)
Other versions
FR2767323A1 (en
Inventor
Bernard Calas
Gerard Grassy
Alain Chavanieu
Michel Kaczorek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synt EM SA
Original Assignee
Synt EM SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9710297A priority Critical patent/FR2767323B1/en
Application filed by Synt EM SA filed Critical Synt EM SA
Priority to AU89889/98A priority patent/AU754617B2/en
Priority to JP2000506230A priority patent/JP2001512739A/en
Priority to CA002298932A priority patent/CA2298932A1/en
Priority to IL13429398A priority patent/IL134293A0/en
Priority to EP98941556A priority patent/EP1003771A1/en
Priority to PCT/FR1998/001757 priority patent/WO1999007728A2/en
Publication of FR2767323A1 publication Critical patent/FR2767323A1/en
Application granted granted Critical
Publication of FR2767323B1 publication Critical patent/FR2767323B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR9710297A 1997-08-12 1997-08-12 LINEAR PEPTIDES DERIVED FROM ANTIBIOTIC PEPTIDES, THEIR PREPARATION AND THEIR USE FOR VECTORIZING ACTIVE SUBSTANCES Expired - Fee Related FR2767323B1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR9710297A FR2767323B1 (en) 1997-08-12 1997-08-12 LINEAR PEPTIDES DERIVED FROM ANTIBIOTIC PEPTIDES, THEIR PREPARATION AND THEIR USE FOR VECTORIZING ACTIVE SUBSTANCES
JP2000506230A JP2001512739A (en) 1997-08-12 1998-08-06 Linear peptides derived from antibiotic peptides, their preparation and their use in mediating active substances
CA002298932A CA2298932A1 (en) 1997-08-12 1998-08-06 Linear peptides derived from antibiotic peptides, preparation and use for vectoring active substances
IL13429398A IL134293A0 (en) 1997-08-12 1998-08-06 Linear peptides derived from antibiotic peptides, preparation and use for vectoring active substances
AU89889/98A AU754617B2 (en) 1997-08-12 1998-08-06 Linear peptides derived from antibiotic peptides, preparation and use for vectoring active substances
EP98941556A EP1003771A1 (en) 1997-08-12 1998-08-06 Linear peptides derived from antibiotic peptides, preparation and use for vectoring active substances
PCT/FR1998/001757 WO1999007728A2 (en) 1997-08-12 1998-08-06 Linear peptides derived from antibiotic peptides, preparation and use for vectoring active substances

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9710297A FR2767323B1 (en) 1997-08-12 1997-08-12 LINEAR PEPTIDES DERIVED FROM ANTIBIOTIC PEPTIDES, THEIR PREPARATION AND THEIR USE FOR VECTORIZING ACTIVE SUBSTANCES

Publications (2)

Publication Number Publication Date
FR2767323A1 FR2767323A1 (en) 1999-02-19
FR2767323B1 true FR2767323B1 (en) 2001-01-05

Family

ID=9510249

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9710297A Expired - Fee Related FR2767323B1 (en) 1997-08-12 1997-08-12 LINEAR PEPTIDES DERIVED FROM ANTIBIOTIC PEPTIDES, THEIR PREPARATION AND THEIR USE FOR VECTORIZING ACTIVE SUBSTANCES

Country Status (7)

Country Link
EP (1) EP1003771A1 (en)
JP (1) JP2001512739A (en)
AU (1) AU754617B2 (en)
CA (1) CA2298932A1 (en)
FR (1) FR2767323B1 (en)
IL (1) IL134293A0 (en)
WO (1) WO1999007728A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1220902A2 (en) * 1998-11-11 2002-07-10 Pantheco A/S Conjugates between a peptide and a nucleic acid analog, such as a pna, lna or a morpholino
DK173006B1 (en) * 1998-11-11 1999-11-01 Ke Burgmann As Method and plant for producing wall material for use in the manufacture of compensators, in particular for flue gas channels, as well as compensator material and compensator produced by the method
FR2786397B1 (en) * 1998-11-30 2003-01-10 Synt Em PEPTIDE VECTORS OF SUBSTANCES THROUGH THE HEMATOENCEPHALIC BARRIER FOR USE IN DIAGNOSIS OR THERAPY OF CNS DISEASE
FR2786398B1 (en) * 1998-11-30 2002-12-27 Synt Em ANTI-CANCER AND ANTI-CHEMORESISTANCE PHARMACEUTICAL COMPOSITION COMPRISING AN ANTI-CANCER AGENT AND AT LEAST ONE PEPTIDE
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
FR2810985B1 (en) * 2000-07-03 2004-12-24 Synt Em AMPHIPATHIC LINEAR PEPTIDES AND COMPOSITIONS CONTAINING THEM
GB0103110D0 (en) 2000-08-25 2001-03-28 Aventis Pharma Inc A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
JP4387669B2 (en) * 2000-10-13 2009-12-16 ザイジェン エス．アー． Intracellular delivery of biological effectors with novel transporter peptide sequences
US7033597B2 (en) * 2000-10-13 2006-04-25 Université de Lausanne Intracellular delivery of biological effectors
FR2821272B1 (en) * 2001-02-23 2004-12-17 Synt Em COMPOUNDS CONSISTING OF AN ANALGESIC MOLECULE LINKED TO A VECTOR CAPABLE OF VECTORIZING THE SAME MOLECULATED THROUGH THE HEMATOENCEPHALIC BARRIER AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2829940A1 (en) * 2001-09-27 2003-03-28 Synt Em New composition, useful for treating central nervous system diseases, comprises an antibody linked to a linear peptide and is able to cross the blood-brain barrier
FR2830016B1 (en) * 2001-09-27 2004-06-25 Synt Em COMPOSITIONS FOR THE VECTORIZATION OF TAXOID DERIVATIVES THROUGH THE HEMATOENCEPHALIC BARRIER AND THEIR USE FOR THE TREATMENT OF CANCERS, PARTICULARLY BRAIN CANCERS
DE60218503T2 (en) 2001-10-16 2007-11-22 Synt:Em (S.A.) USE OF PEPTIDE VECTORS TO IMPROVE THE IMMUNE RESPONSE AGAINST ANTIGENS
FR2836474B1 (en) * 2002-02-22 2004-12-24 Synt Em COMPOUNDS, COMPOSITIONS AND METHOD FOR TRANSPORTING CYCLOSPORIN MOLECULES THROUGH THE HEMATOENCEPHALIC BARRIER
FR2840810B1 (en) * 2002-06-18 2005-02-11 Synt Em COMPOSITION FOR THE TRANSFER OF THERAPEUTIC MOLECULES TO LUNGS AND THEIR USE IN THE TREATMENT OF LUNG CANCERS AND PULMONARY DISEASES
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
FR2914928B1 (en) * 2007-04-12 2009-07-10 Univ Victor Segalen Bordeaux 2 PROCESS FOR PREPARING A CARRIER FOR IMMOBILIZATION OF A CELL, SUCH A CARRIER AND USES THEREOF
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
ES2613866T3 (en) 2008-06-12 2017-05-26 Centre For Addiction And Mental Health Compositions and methods to modulate the interaction and function of the D1-D2 dopamine receptor
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
WO2012048721A1 (en) 2010-10-14 2012-04-19 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
JP2016523274A (en) 2013-06-26 2016-08-08 ザイジェン インフラメーション リミテッド Use of novel cell penetrating peptide inhibitors of the JNK signaling pathway to treat various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE107170T1 (en) * 1988-10-21 1994-07-15 Philadelphia Children Hospital COMPOSITION AND TREATMENT USING BIOLOGICALLY ACTIVE PEPTIDES AND CERTAIN ANIONS.
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
US5804558A (en) * 1993-07-20 1998-09-08 University Of California Protegrins
US5580852A (en) * 1993-12-17 1996-12-03 Pioneer Hi-Bred International, Inc. Derivatives of tachyplesin having inhibitory activity towards plant pathogenic fungi
BR9611434A (en) * 1995-11-16 2000-10-24 Shell Int Research Polydiene polymer coating compositions with cross-linkable hydroxy functionality and a process for preparing them
US5994306A (en) * 1995-11-22 1999-11-30 Intrabiotics Pharmaceuticals, Inc. Fine-tuned protegrins

Also Published As

Publication number Publication date
FR2767323A1 (en) 1999-02-19
CA2298932A1 (en) 1999-02-18
WO1999007728A2 (en) 1999-02-18
WO1999007728A3 (en) 1999-06-24
EP1003771A1 (en) 2000-05-31
IL134293A0 (en) 2001-04-30
AU8988998A (en) 1999-03-01
AU754617B2 (en) 2002-11-21
JP2001512739A (en) 2001-08-28

Similar Documents

Publication Publication Date Title
FR2767323B1 (en) LINEAR PEPTIDES DERIVED FROM ANTIBIOTIC PEPTIDES, THEIR PREPARATION AND THEIR USE FOR VECTORIZING ACTIVE SUBSTANCES
IS5953A (en) Pharmaceutical preparations from microplated eplerenones
DE59701787D1 (en) MEDICINE DOSING SYSTEM
DK0981375T3 (en) Pharmaceutical preparations containing plasma protein
DE122005000024I1 (en) Darifenacin containing pharmaceutical preparations.
FI973244A (en) Pharmaceutical preparations for intranasal use
NO986023D0 (en) Water-based pharmaceutical preparations
BR9805993B1 (en) aerosol pharmaceutical composition.
HUP0103793A3 (en) N-(2-aryl-propionyl)-sulfonamids, their use and pharmaceutical preparations containing them
DE69518324T2 (en) HIGHLY ACTIVE POLYETHYLENE CATALYSTS
NO20004391D0 (en) Fragrance-enhancing preparations for cosmetic products
DE59608798D1 (en) ENDOPARASITICIDAL AGENTS
ID22228A (en) 16-HYDROXY-11- (DISUBSTITUSIFENIL) -ESTRA-4,9-DIENA
DE69734043D1 (en) Perfume delivery system
ID18793A (en) HOLDING INGREDIENTS FOR PESTICIDES
ID16781A (en) PHARMACEUTICAL FORMULATIONS
DE69926012D1 (en) PHARMACEUTICAL PREPARATIONS
IT1302969B1 (en) PACKAGING FOR MEDICINAL SUBSTANCES
NO995838D0 (en) New heteroethynylene compounds and pharmaceutical and cosmetic preparations containing the same
DE69715152D1 (en) Capsules containing whey protein
EE9800275A (en) Prolonged-release pharmaceutical preparations containing misolastin
DK1041966T3 (en) Pharmaceutical preparations comprising zafirlukast
DE69906934D1 (en) PHARMACEUTICAL PREPARATIONS
FI972965A (en) New peptides, their preparation and use
DE29607273U1 (en) Active ingredient complex for cosmetics

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20100430